Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05165173
Other study ID # IRB202102986
Secondary ID OCR41655
Status Completed
Phase N/A
First received
Last updated
Start date May 22, 2023
Est. completion date November 18, 2023

Study information

Verified date June 2024
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal is to enhance vitamin D status in a safe and effective manner. A 3-week randomized comparator-controlled trial among a cohort of adults with CKD (stages 3-5) (n=24) will test the main objective: Evaluate the bioefficacy of D3 in micro- and nanoparticles (4000IUs) in almond milk with the sub-objective of: Explore the effect of D3 in micro- and nanoparticles (4000IUs) in almond milk on inflammation markers CRP, TNF-α and IL-6.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date November 18, 2023
Est. primary completion date November 18, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adults who have been diagnosed with CKD - have no GI disorders or GI disturbances - age 18 years or older - no food allergies or dietary restrictions - all with no contraindications to consuming anything by mouth as per their physician Exclusion Criteria: - no diagnosis of CKD - GI disorders - gastrointestinal disturbances - under 18 years old - food allergies to almonds - Dietary restrictions as medically indicated - trouble chewing/swallowing as confirmed by physician

Study Design


Intervention

Dietary Supplement:
NanoD4CKD
Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
MicroD4CKD
Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.

Locations

Country Name City State
United States University of Florida Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vitamin D baseline to end line in the concentration of serum 25(OH)D3 between and within the control and intervention groups. 21 days
Secondary Calcium baseline to end line in the concentration of serum calcium between and within the control and intervention groups. 21 days
Secondary PTH baseline to end line in the concentration of serum PTH between and within the control and intervention groups. 21 days
Secondary parent vitamin D baseline to end line in the concentration of serum parent vitamin D between and within the control and intervention groups. 21 days
Secondary IL-6 baseline to end line in the concentration of serum IL-6 between and within the control and intervention groups. 21 days
Secondary C-reactive protein baseline to end line in the concentration of C-reactive protein between and within the control and intervention groups. 21 days
Secondary TNF-alpha baseline to end line in the concentration of serum TNF-alpha between and within the control and intervention groups. 21 days
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT02922361 - Spending and Outcomes for Complex Medicare Advantage Patients
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Completed NCT01930396 - Use of Tinzaparin for Anticoagulation in Hemodialysis Phase 4
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Completed NCT01922843 - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis Phase 2
Not yet recruiting NCT01674660 - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients N/A
Not yet recruiting NCT01157260 - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Phase 4
Completed NCT01209403 - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Phase 4
Completed NCT00753116 - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension Phase 1
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Completed NCT00534144 - Comparison Between Effects of Two Iron Preparations on Protein in the Urine Phase 1
Completed NCT00528788 - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Phase 4
Completed NCT00226902 - Vascular Reactivity in Kidney Disease Patients N/A
Completed NCT00382044 - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients N/A
Recruiting NCT00235287 - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Phase 4
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00071214 - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis Phase 3
Completed NCT00049907 - Cardiac and Renal Disease Study (CARDS) N/A
Completed NCT00006297 - Risk Factors for CV Disease in a Dialysis Cohort N/A